Morgan Stanley provided positive research ratings on Exelixis stock, with MarketBeat aggregating the consensus data.
4 reports, 2 independent
Updated Sep 17
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley provided positive research ratings on Exelixis stock, with MarketBeat aggregating the consensus data.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Exelixis participated in a Morgan Stanley conference and is assessing international assets.1 source
Morgan Stanley increased its stake in Exelixis.1 source
Morgan Stanley provided positive ratings for Exelixis, which MarketBeat aggregated.1 source
Keep exploring
The entities involved
-
Morgan Stanley
U.S. investment bank
-
Exelixis
American biotechnology company
-
MarketBeat
American personal finance blog
Related events
- MarketBeat provided consensus rating data for Colony Bankcorp, Inc.
- Barclays and UBS raised price targets for Exelixis stock, noting that AI stocks are benefiting from Trump-era tariffs.
- MarketBeat aggregates analyst ratings for the company Ecopetrol.
- Spark I Acquisition Co. filed reports with the SEC and MarketBeat reported its average stock rating.
- MarketBeat provided average rating data for Quince Therapeutics, Inc., following a stock rating boost from Raymond James Financial.